Literature DB >> 8611732

Natural killer (NK)-cell function and antileukemic activity of a large population of CD3+/CD8+ T cells expressing NK receptors for major histocompatibility complex class I after "three-loci" HLA-incompatible bone marrow transplantation.

N Albi1, L Ruggeri, F Aversa, C Merigiola, A Tosti, R Tognellini, C E Grossi, M F Martelli, A Velardi.   

Abstract

We have shown that addition of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to the marrow inoculum allows engraftment of T-cell depleted, "three loci" HLA-incompatible marrow transplants for acute leukemia. The event-free survival of patients at high risk for potential of this transplant. Tumor-cell lysis by natural killer (NK) cells is regulated by inhibitory receptors for specific HLA class I alleles. Here, we report the postgrafting emergence of a large, donor-type CD3+/CD8+ T-cell receptor (TcR)-alpha beta+ cell population, barely detectable in normal subjects, that expresses 58 kD, "p58," NK receptors for HLA-C locus alleles. Analysis of > 900 clones revealed that 40% to 80% of these T cells exhibit NK-like function, i.e., they lysed class I- targets and were functionally blocked by class I alleles on target cells. Monoclonal antibody-mediated blocking of class I recognition by these cells induced lysis of HLA-protected, autologous targets. The class I-mediated inhibitory signaling through the NK receptors also blocked TcR/CD3-triggered cytotoxicity of these cells, indicating that their antigen-specific responses may be impaired. However, the NK-like function of these cells allows them to discriminate normal cells, protected from lysis, from leukemic cells that were lysed and may be targets for a graft-versus-leukemia effect.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8611732

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Natural killer cell acceptance of H-2 mismatch bone marrow grafts in transgenic mice expressing HLA-Cw3 specific killer cell inhibitory receptor.

Authors:  A Cambiaggi; C Verthuy; P Naquet; F Romagné; P Ferrier; R Biassoni; A Moretta; L Moretta; E Vivier
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

Review 2.  Potential role of natural killer cell receptor-expressing cells in immunotherapy for leukemia.

Authors:  Junji Tanaka; Masahiro Asaka; Masahiro Imamura
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

Review 3.  HLA-C revisited. Ten years of change.

Authors:  C S Falk; D J Schendel
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

Review 4.  Immunological reconstitution and immunoregulatory cells in hematopoietic stem cell transplantation.

Authors:  Masahiro Imamura
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

5.  Interleukin-10-induced CD8 cell proliferation.

Authors:  A W Rowbottom; M A Lepper; R J Garland; C V Cox; E G Corley
Journal:  Immunology       Date:  1999-09       Impact factor: 7.397

6.  Blockade of individual Notch ligands and receptors controls graft-versus-host disease.

Authors:  Ivy T Tran; Ashley R Sandy; Alexis J Carulli; Christen Ebens; Jooho Chung; Gloria T Shan; Vedran Radojcic; Ann Friedman; Thomas Gridley; Amy Shelton; Pavan Reddy; Linda C Samuelson; Minhong Yan; Christian W Siebel; Ivan Maillard
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

Review 7.  Immunoregulatory cells for transplantation tolerance and graft-versus-leukemia effect.

Authors:  Masahiro Imamura; Junji Tanaka
Journal:  Int J Hematol       Date:  2003-10       Impact factor: 2.490

8.  Corruption of dendritic cell antigen presentation during acute GVHD leads to regulatory T-cell failure and chronic GVHD.

Authors:  Lucie Leveque-El Mouttie; Motoko Koyama; Laetitia Le Texier; Kate A Markey; Melody Cheong; Rachel D Kuns; Katie E Lineburg; Bianca E Teal; Kylie A Alexander; Andrew D Clouston; Bruce R Blazar; Geoffrey R Hill; Kelli P A MacDonald
Journal:  Blood       Date:  2016-06-23       Impact factor: 22.113

9.  Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.

Authors:  Francois Romagné; Pascale André; Pieter Spee; Stefan Zahn; Nicolas Anfossi; Laurent Gauthier; Marusca Capanni; Loredana Ruggeri; Don M Benson; Bradley W Blaser; Mariella Della Chiesa; Alessandro Moretta; Eric Vivier; Michael A Caligiuri; Andrea Velardi; Nicolai Wagtmann
Journal:  Blood       Date:  2009-06-24       Impact factor: 22.113

10.  Natural killer cell-mediated lysis of autologous cells modified by gene therapy.

Authors:  C Liberatore; M Capanni; N Albi; I Volpi; E Urbani; L Ruggeri; A Mencarelli; F Grignani; A Velardi
Journal:  J Exp Med       Date:  1999-06-21       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.